Table 2.
Treatment response, TTP, and OS by regimen and treatment line
| First-line regimen | N | CR, n (%) | PR, n (%) | SD, n (%) | PD, n (%) | Median TTP (months) | Median OS (months) |
|---|---|---|---|---|---|---|---|
| Total | 240 | 11 (5) | 119 (50) | 53 (22) | 57 (24) | 7.0 | 16.3 |
| Fluoropyrimidine-platinum | 164 | 8 (5) | 89 (54) | 35 (21) | 32 (20) | 8.1 | 19.3 |
| FOLFIRI | 19 | 2 (11) | 7 (37) | 5 (26) | 5 (26) | 6.0 | 15.6 |
| Fluoropyrimidine | 30 | 1 (3) | 13 (43) | 9 (30) | 7 (23) | 6.4 | 19.7 |
| FOLFIRINOX | 6 | 0 (0) | 5 (83) | 1 (17) | 0 (0) | 7.0 | 17.3 |
| Othera | 21 | 0 (0) | 5 (24) | 3 (14) | 13 (62) | 2.9 | 8.8 |
| ≥Second-line therapy | N | CR, n (%) | PR, n (%) | SD, n (%) | PD, n (%) | TTP (months) | OS (months) |
|---|---|---|---|---|---|---|---|
| Total | 267 | 3 (1) | 48 (18) | 63 (24) | 153 (57) | 2.9 | 11.0 |
| FOLFIRI | 122 | 1 (1) | 32 (26) | 33 (27) | 56 (46) | 3.9 | 13.0 |
| Taxane based (mono/combo)b | 34 | 0 (0) | 7 (21) | 9 (26) | 18 (53) | 2.4 | 8.8 |
| Fluoropyrimidine-platinum | 9 | 0 (0) | 1 (13) | 5 (56) | 3 (38) | 6.4 | 19.8 |
| Anti-EGFR monotherapy | 11 | 0 (0) | 0 (0) | 1 (9) | 10 (91) | 2.6 | 8.5 |
| Anti-PD-1 | 22 | 2 (9) | 3 (14) | 4 (18) | 13 (59) | 2.9 | 15.4 |
| Gemcitabine (mono/combo)c | 19 | 0 (0) | 2 (11) | 4 (21) | 13 (68) | 2.3 | 8.4 |
| TAS-120 or regorafenib | 5 | 0 (0) | 0 (0) | 1 (20) | 4 (80) | 1.9 | 4.8 |
| Othera | 45 | 0 (0) | 2 (4) | 6 (13) | 37 (80) | 2.1 | 9.1 |
a
Other agents are described in the Supplementary Data, available at https://doi.org/10.1016/j.esmoop.2021.100132.
b
Taxane-based combinations with gemcitabine (n = 11), capecitabine (n = 2).
c
Gemcitabine-based combinations with oxaliplatin (n = 1), capecitabine (n = 2), irinotecan (n = 2); and cisplatin (n = 1).